Call: (979) 848-0800
DELIVERING, EXPANDING, ADVANCING The science of radiopharmaceuticals


August 2020

Monopar and NorthStar partner with IsoTherapeutics for the manufacturing of potential therapeutics for severe COVID-19.


November 2019

Q BioMed Inc. announced that IsoTherapeutics Group, LLC has been approved as a contract manufacturer for it’s FDA approved non-opioid cancer bone pain drug Strontium-89 Chloride USP. The full news release can be viewed here.


June 2019

IsoTherapeutics Group, LLC participated in and had an exhibit at the SNMMI 2019 Annual Meeting in Anaheim, CA.


September 2018

CycloSam Therapeutics, Inc. changes name to IGL Pharma, Inc.


June 2018

IsoTherapeutics Group, LLC participated in and had an exhibit at the SNMMI 2018 Annual Meeting in Philadelphia, PA.


September 2017

Jim Simon, V.P. and CSO for IsoTherapeutics Group, LLC was an invited speaker at the UPPI, LLC Annual Members Meeting in Sarasota, FL where he spoke about current radiopharmaceutical research.


June 2017

CycloSam Therapeutics, Inc. was incorporated in Delaware.


June 2017

IsoTherapeutics Group, LLC was selected to exhibit its CycloSam® technology at the Biotechnology Innovation Organization (BIO) conference in San Diego.


June 2017

IsoTherapeutics Group, LLC participated and had an exhibit at the SNMMI 2017 Annual Meeting in Denver, CO.


October 2016

IsoTherapeutics Group, LLC spun out its CycloSam® bone agent technology into a separate company, CycloSam Therapeutics, LLC after securing seed funding from private investors>.


June 2016

IsoTherapeutics Group, LLC participated in and had an exhibit at the SNMMI 2016 Annual Meeting in San Diego, CA.


June 2015

IsoTherapeutics Group, LLC participated in and had an exhibit at the SNMMI 2015 Annual Meeting in Baltimore, MD.


August 2014

Jim Simon and George St. George are attending and presenting at the American Nuclear Society Conference Aug 24-28, 2014 in Chicago.


May 2014

IsoTherapeutics joins The Gabriel Institute to visit Skylar one year after her treatment.

Skylar received a novel treatment for bone cancer being developed by IsoTherapeutics and The Gabriel Institute.  The efficacy of this novel therapy is being evaluated by ongoing clinical trials which are looking promising.



IsoTherapeutics Group invites everyone to stop by Booth 1813

at the SNMMI Show in St Louis June 7-11, 2014


April 2014

IsoTherapeutics Group was proud to collaborate with the University of Missouri in treating this St Bernard dog using our “Liquid Brachytherapy” technology. 

April 2014

IsoTherapeutics Group is a proud partner with Actinium Pharmaceutical for further development of Actimab-A manufacturing.

View API announcement 4-7-14


March 2014

IsoTherapeutics Group awarded NIH grant for advancing treatment of bone cancer

IsoTherapeutics Group, LLC has been awarded a Phase II SBIR grant for its development of CycloSam® Sm-153-DOTMP for treating bone cancer.  Early findings show that CycloSam is a bone seeking agent indicated not only for the relief of pain from bone metastases, but also for treating primary osteosarcoma.  These findings were established as a result of a Phase I NCI SBIR research grant in 2010-11.1   The success with this initial study culminated in a second SBIR award for furthering the development of CycloSam, specifically the chemistry, manufacture and control information, development of a non-clinical toxicology study program, and preparation of a Phase 1 clinical protocol for first-in-human clinical studies with CycloSam.  Based on our early findings in studies performed in canines bearing spontaneous osteosarcomas, IsoTherapeutics’ Scientists and advisors have reason to believe that CycloSam will prove beneficial and advantageous to patients with bone metastases.  It induces less myelotoxicity than Quadramet® Sm-153-EDTMP and potentially allows concurrent CycloSam and chemotherapy treatment.

1 Supported by the National Cancer Institute R43CA150601


March 2014

IsoTherapeutics Group Awarded DOE SBIR Phase 1 for developing method for producing high specific activity Sn-177m

R. Keith Frank, Ph.D., CEO of IsoTherapeutics Group, is pleased to announce that the DOE has awarded a Phase I SBIR grant to IsoTherapeutics for developing a method for producing high specific activity (SA) Sn-117m.  The technical approach for producing commercially useful amounts of high purity Sn-117m is to perform electromagnetic enrichment of low SA reactor-produced material.  John D’Auria, Ph.D., principal investigator for the project, commented that Electro-Magnetic Isotope Separation (EMIS) is routinely used in the production of enriched stable isotopes and in mass spectrometry; however, the successful development of an economically viable facility for processing relatively short-lived radioactive medical isotopes presents new challenges.  We are developing the technique in a related Phase II SBIR project that is producing high SA samarium-153 for the first time.  While our experience with Sm-153 gives us great confidence in the general approach, the physical chemistry of each element presents unique challenges for each radioisotope being considered.

IsoTherapeutics, with its customers/collaborators, have been engaged with radiolabeling of Sn-117m with proteins for a number of years.  This radioisotope is considered a theranostic isotope that is suitable for both diagnostic and therapeutic applications.  Its low energy gamma emissions (158 keV) can be imaged using standard gamma cameras and collimators routinely used for technetium-99m (140 keV).  For therapy, its conversion electrons (127, 129 and 152 keV; abundance 65, 12 and 26% respectively) exhibit high linear energy transfer over a short range (<300 micron), which minimizes damage to healthy tissue.  These emissions, along with its 13.6 day half-life, make Sn-117m of interest in a variety of applications in oncology, rheumatology, ophthalmology, and neurology according to Dr. Jaime Simón, Ph.D., Chief Scientific Officer of IsoTherapeutics.


November 5, 2011

Latest Publication

Bioconjugate Chemistry today published “Comparison of Pretargeted and Conventional CC49 Radioimmunotherapy Using 149Pm, 166Ho, and 177Lu.”

View Paper >>

September, 2011

Dillon Kopecky presented McMillan Memorial Scholarship

Dillon Kopecky, a chemistry student at Brazosport College, was presented the 3rd annual McMillan Memorial Scholarship

June, 2011

IsoTherapeutics Group Announces New cGMP Capabilities

IsoTherapeutics Group has expanded its facilities and capabilities to include cGMP manufacturing. Our focus will be clinical trial scale radiopharmaceuticals.

December 7, 2010

Sophia Nadirshina presented McMillan Memorial Scholarship

Sophia Nadirshina, Keith Frank, Edna McMillan, Serena Andrews

Sophia Nadirshina recently received the IsoTherapeutics Group Kenneth McMillan Memorial Scholarship. Nadirshina, a chemistry major, plans to transfer to a university next school year followed by dental school.

April 8, 2010

“Liqiud Brachytherapy” Treats Osteosarcoma

PET/CT Image of OS in Distal Radius

“Liquid Brachytherapy,” a novel technology for the treatment of inoperable tumors, jointly developed by IsoTherapeutics and The Gabriel Institute, has now been evaluated in 16 cases of canine osteosarcoma with very promising results. The latest treatment on “Juno,” a 160 lb Saint Bernard was preformed at the new Texas A&M Institute for Preclinical Studies (TIPS). This was, in fact, the first clinical case treated at the new facility. TIPS brings state-of-the-art imaging capabilities to our efforts to move this technology forward. Juno’s treatment was featured recently in MIT Technology Review.

November 23, 2009

Sara Barge presented McMillan Memorial Scholarship

Edna McMillan, Sara Barge, Keith Frank, Jim Simon

Sara Barge, Biomedical Science major at Brazosport College, was presented with the first annual Kenneth McMillan Memorial Scholarship.

October 18, 2009

Veterinary Cancer Society – Austin, TX

“Intralesional Liquid Brachytherapy in Dogs with Appendicular Osteosarcoma”

View Presentation >>

August 20, 2009

Kenneth McMillan Memorial Scholarship Awarded

Congratulations to Sara Barge, a Biomedical Science major at Brazosport College. She is the first recipient of the Kenneth McMillan Memorial Scholarship.

July 24, 2009

No Relationship with PharmaCom BioVet

Due to many recent inquiries about a relationship between IsoTherapeutics and PharmaCom BioVet Inc., IsoTherapeutics wishes to state that we have no current relationship with this company.

June 11, 2009

Kenneth McMillan Memorial Scholarship

The Kenneth McMillan Memorial Scholarship is being initiated to honor the memory of our late long-term friend and colleague Kenneth McMillan. The scholarship will be awarded annually to a deserving high school senior from the Brazosport Independent School District. Kenneth had a long career at The Dow Chemical Company, working along side us for over twenty years. When we formed IsoTherapeutics, Kenneth joined us and served as our Radiation Safety Officer and Laboratory Director until his untimely passing in December of 2008.

More Information >>

November 6, 2008

Texas Life Science Conference – Houston, TX

“Liquid Brachytherapy”

View Presentation >>

August 10, 2008

Conference on the Application of Accelerators in Research and Industry

“Liquid Brachytherapy – Direct Administration of Therapeutic Isotopes into Tumors”

View Presentation >>

June 16, 2008

Society of Nuclear Medicine Annual Meeting – New Orleans, LA

“Liquid Brachytherapy – Direct Administration of Therapeutic Isotopes into Tumors”

View Presentation >>

April, 2008

First Dog Trial

University of Missouri School of Veterinary Medicine. Dr. Carolyn Henry and Dr. James Latimer


A small company with high caliber people. This company helped me address critical questions posed by the FDA.

Ebrahim S. Delpassand, M.D.
Chairman & Medical Director Excel Diagnostics

IsoTherapeutics has proven to be a partner able to adapt quickly to FUJIFILM's changing needs. Within two weeks, they had documentation in place for the preparation of two new blood testing kits, and prepared GMP batches of each for our clinical sites.

Takeaki Suzuki, Ph.D.
Associate Director, Drug Development, Head of Operations, FUJIFILM Pharmaceuticals USA, Inc.

The combination of R&D, cGMP and small animal testing facilities makes IsoTherapeutics the ideal partner for our radiopharmaceutical programs - from initial development to commercialization. The skills that IsoTherapeutics have brought to our product development programs over the past decade have proven to be a major contribution to our success.

Nigel R. Stevenson, Ph.D.
COO, Serene, LLC

Contact Us

IsoTherapeutics Group, LLC
1004 S. Velasco St.
Angleton, TX 77515

Phone (979) 848-0800
Fax (979) 848-0807